What are the Best 10x Potential Stocks Right Now?
If I had to pick 10 stocks that could genuinely 10x over the next 3–5 years, I’d go with CoreWeave (CRWV), Nebius Group (NBIS), Oscar Health (OSCR), AST SpaceMobile (ASTS), Rocket Lab (RKLB), IREN (IREN), Zeta Global (ZETA), Xpeng (XPEV), Lemonade (LMND), and Ambarella (AMBA). Some of these are already running hard. Others are still early. All of them have real reasons to be on this list — not just hype.
Why AI, Cloud and Space Stocks Matter Right Now
Three things dropped simultaneously this week that made me want to write this.
First: Nasdaq announced on June 11 that CoreWeave, Nebius, and Rocket Lab are being added to the Nasdaq-100 effective June 22. Every index fund and ETF tracking the Nasdaq-100 has to buy these stocks. That’s automatic buying pressure regardless of sentiment.
Second: AST SpaceMobile is launching its BlueBird 8, 9, and 10 satellites on June 17 from Cape Canaveral on a SpaceX rocket. Each successful launch gets them closer to commercial service.
Third: Oscar Health just posted its best quarter ever. Net income of $679 million, up 146%. Membership hit 3.17 million. The AI health insurance model is actually working at scale.
All of this at once. That’s why this list is relevant right now and not just a generic “future growth” wishlist.
Three trends are accelerating simultaneously, and this convergence is rare:
- AI infrastructure spending is exploding. By 2026, AI-enabled workflows will expand from 3% to 25% of enterprise operations, and agentic AI is becoming the main investment focus. Enterprises worldwide are expected to invest $632 billion in AI solutions by 2028 at a 29% CAGR.
- Cloud providers can’t build data centers fast enough. Nebius is selling out capacity quarters in advance. CoreWeave has $99.4 billion in backlog. Ciena’s direct cloud customer revenue grew 70% year over year. Supply is the constraint, not demand.
- Space is becoming commercial infrastructure. SpaceX’s looming IPO (expected June 2026 at a $1.75–2 trillion valuation) is pulling the entire sector higher. Rocket Lab signed more launch contracts in Q1 2026 than in all of 2025.
Best 10x Potential Stocks Deep Analysis
All Stocks are basis of my personal analysis and research. Please Invest at your own risk.
- Core Weave (CRWV)
Here’s the simplest way to understand CoreWeave.
Microsoft, Amazon, and Google have massive cloud infrastructure — but AI companies are demanding more GPU compute than even those giants can supply fast enough. CoreWeave is who they turn to for the overflow.
The company went public in March 2025. Since then, revenue has doubled every single quarter. Last quarter came in at $2.08 billion — up 111% from the same time last year. Bank of America has a Buy with a $100 price target. 23 out of 36 analysts rate it Buy or higher.
Just this week, CoreWeave announced it’s raising $3.5 billion in debt to fund more data centers. Aggressive move — but it tells you the demand they’re seeing justifies it.
The one thing I watch closely: most of their revenue comes from a small number of customers. Microsoft is a huge chunk. If Microsoft builds enough GPU capacity in-house and pulls back CoreWeave orders, that hurts. Customer concentration is the main risk here.
This is probably the most “institutional quality” pick on the list. The growth is real, the Nasdaq-100 inclusion validates it. But the easy money was made earlier. You’re buying a more expensive stock today than 6 months ago.
2. Nebius Group (NBIS)
Most people don’t know the backstory on Nebius. Let me explain.
Nebius came out of Russia’s Yandex — basically Russia’s Google. When the Ukraine war started, Yandex spun off all its international assets. Nebius is that spinoff. It completely pivoted to building AI cloud infrastructure across Europe, and now aggressively into the UK.
The growth numbers are genuinely staggering. Revenue grew 684% year-over-year. They’re projecting an annual revenue run rate of $7 billion to $9 billion. They just announced a £1.7 billion UK AI buildout. And they’re one of the first companies getting access to NVIDIA’s next-generation Vera Rubin chips in H2 2026.
Stock is up 165% year-to-date. 342% over the last 12 months.
I know what you’re thinking — “hasn’t this already run too much?” Maybe. But Morgan Stanley just initiated a Buy. Northland Securities also has a Buy this month. And Nasdaq-100 inclusion starting June 22 brings more institutional money automatically.
The risk: scaling up GPU infrastructure costs a lot. If financing gets tight or NVIDIA supply delays happen, projections fall apart. This requires flawless execution.
The revenue growth rate here is the most impressive of any company on this list. If they hit that $7B–$9B run rate, the stock is still undervalued. But it requires everything to go right.
3. Oscar Health (OSCR)
I want to explain why Oscar Health is on a “10x stocks” list when it’s already had a big run this year.
Oscar built a health insurance company from scratch on technology. No legacy systems. No old-school claims processing. AI handles everything. Members use an app. The whole model is designed to reduce the medical loss ratio (MLR) — the percentage of premium revenue paid out as claims. Lower MLR means more profit.
For years, Wall Street asked: “okay, cool model, but can you actually make money?”
Q1 2026 answered that. Revenue hit $4.65 billion, up 52.7%. Net income was $679 million, up 146%. The medical loss ratio improved from 75.4% to 70.5% — a massive efficiency gain. Membership hit 3.17 million, up 55% year-over-year. Full-year 2026 revenue guided at $18.7 billion to $19 billion.
Stock is up over 80% in 2026. Analyst price targets average around $20–$21, and it’s trading around $27. So some people think it’s stretched.
But here’s what I keep thinking: a tech company that’s also a profitable health insurer at $19 billion revenue scale — how many of those exist? Basically one. The market is still figuring out how to value that.
The Q2 medical loss ratio is what I’m watching most carefully. Q1’s 70.5% was exceptional — management guided it normalizes to 82–83% for the full year as summer health utilization picks up. If Q2 MLR comes in better than feared, there’s another leg up. If it blows out, the stock gives back gains quickly.
4. IREN (IREN)
IREN started as a bitcoin miner running on renewable energy. But over the last year, they’ve pivoted aggressively toward AI data centers — and the numbers show why.
Revenue is projected to grow around 120% this year. Then another 151% next year. Think about that — roughly tripling revenue in two years.
Here’s what’s interesting about their setup: they already have the energy infrastructure. Building a data center is only half the problem. The other half is finding cheap, reliable power. IREN already solved that. It gives them a cost advantage over competitors scrambling for power sources.
WallStreetBets included IREN in their 2026 community index alongside ASTS, RKLB, and NBIS. Retail conviction is real here.
This is the most underrated name on the list. Not getting the same coverage as CoreWeave or Nebius, but the growth projections are comparable. The risk is execution — transitioning from crypto mining to AI infrastructure is genuinely hard. But if they pull it off, this could be the biggest percentage gainer on the list.
5. AST Space Mobile
Let me explain what AST SpaceMobile is building, because it sounds crazy until you understand it.
Right now, if you go somewhere without cell coverage — rural area, middle of the ocean, a developing country — your phone doesn’t work. The only alternatives are expensive satellite devices.
AST is building a satellite network that connects directly to your existing phone. No new hardware. No app download. Just your regular phone getting a signal from a satellite in space.
The addressable market: basically every mobile phone subscriber on earth who has ever had no signal. That’s a $43.3 billion market by 2034, growing at 32.7% per year. AST has partnerships with telecom operators serving 2.8 billion subscribers globally. They have FCC authorization for up to 248 satellites and contracted revenue commitments above $1.2 billion.
They’re launching BlueBird 8, 9, and 10 on June 17. Commercial service is targeted for H2 2026.
Now the honest part: this is the riskiest stock on this list. Down roughly 35% since late January despite big gains last year. A satellite (BlueBird 7) was lost. Insiders sold over $270 million worth of shares in 90 days — that’s a yellow flag. The company burned through $191 million in net losses in Q1 alone.
Some analysts see 40%+ upside based on DCF. Barclays has an Underweight with a $60 target.
Small position or no position depending on your risk tolerance. If it works, the upside is massive. If satellite deployment faces more delays, the stock can drop significantly. If you buy this, treat it as a speculative bet — not a core holding.
6. Rocket Lab
Rocket Lab is the least exciting stock on this list. That’s actually why I like it.
They launch rockets. They build satellites. They sell space systems components. Real revenue from real contracts with real clients. No “if this technology works” uncertainty like ASTS.
Up 64.5% year-to-date in 2026. Just got added to the Nasdaq-100. Government contracts keep expanding. They’re developing a larger rocket called Neutron that opens up new revenue categories.
This is the “sleep well at night” space stock. Not the one that 10x’s fastest — but the most likely to still be a solid business in 5 years regardless of how the more speculative space plays go.
7. Zeta Global (ZETA)
Zeta runs an AI marketing platform. Brands use it to find customers, keep them, and grow them. The company processes billions of data points daily to predict consumer behavior and helps brands act on it.
This is B2B, which means it’s less flashy than consumer apps but much stickier. Enterprise clients sign multi-year contracts. And as AI gets better at predicting what people will buy, Zeta’s platform becomes more valuable.
This is probably the quietest name on this list — and I think that’s the opportunity.
One I’d put in “watch and learn” mode before buying. The AI marketing space is real, the data moat is real, but you need to understand their competitive positioning against Salesforce and Adobe before committing.
8. Xpeng (XPEV)
I’ll be straight: Xpeng is the highest geopolitical risk on this list for investors outside China.
But from a technology standpoint, Xpeng is doing genuinely impressive things with autonomous driving. Their XNGP system is one of the most advanced in China. Software-defined vehicles that get smarter over time. Aggressive roadmap including flying cars.
The Chinese EV market is brutally competitive — BYD, NIO, Li Auto, Tesla. But Xpeng is carving out a tech-first premium niche.
The risk here isn’t the technology. It’s US-China trade tensions, tariffs, and uncertainty around Chinese ADRs. If you’re comfortable with that layer of risk, the tech upside is real. If that makes you nervous, there are cleaner picks on this list.
9. Lemonade (LMND)
If you understand the Oscar Health thesis — AI-powered insurance eventually becomes more profitable because technology cuts costs — you understand Lemonade.
Lemonade does renters, homeowners, pet, auto, and life insurance through an app. AI processes claims fast. They’ve been unprofitable for years, but loss ratios are improving.
The question is whether Lemonade is the “next Oscar Health” re-rating waiting to happen. Oscar just proved the model works at scale. Lemonade is earlier in that journey.
I’d pair this mentally with OSCR. If Oscar’s Q2 and Q3 results hold up, Lemonade becomes more interesting because the same technology thesis is validated. If you’re not yet convinced on AI insurance, wait for more Oscar data before touching LMND.
10. Ambarella (AMBA)
Ambarella makes chips for AI video processing. Security cameras, robotics, autonomous vehicles, smart home devices — anything that needs to process visual data locally without sending everything to the cloud.
This is called edge AI. AI running on the device itself. As autonomous vehicles, smart cities, and industrial robots scale up, demand for chips that process video at low power grows with it.
Ambarella isn’t competing with NVIDIA in data centers. They’re in a narrower lane — and that specialization is a moat.
This is my “boring compounder” pick. Won’t 10x in a year. But as edge AI applications multiply over the next 5 years, Ambarella is one of very few chip companies building specifically for that market.
Bull Case vs. Bear Case
If everything goes right:
CoreWeave’s revenue doubles again in 2027. Nebius hits its $7–9B run rate. Oscar Health posts a full profitable year for the first time. AST SpaceMobile launches commercial service and converts $1.2B in contracts into real cash. Three or four names from this list deliver 5x–10x over 3 years.
If things go wrong:
AI infrastructure spending slows as companies question ROI. Interest rates stay high, crushing growth multiples. AST hits another satellite delay. Oscar’s H2 MLR blows out. You’re holding a portfolio of high-beta losers.
The truth sits somewhere in between. This is why position sizing matters more than stock picking for a list like this.
My Research & opinion
Here’s what I actually think.
Three names on this list (CoreWeave, Nebius, Rocket Lab) are already validated by the market. Nasdaq-100 inclusion says “these are real companies now.” The easy money was made 6–12 months ago. You can still own them, but you’re buying after a big run.
The more interesting opportunity is in names that haven’t had their moment yet.
IREN is generating the same AI infrastructure demand signals as Nebius and CoreWeave — but getting a fraction of the coverage. Lemonade is sitting on the same thesis Oscar just proved — and nobody’s pricing that in yet. Ambarella is quietly building in an edge AI niche that nobody’s competing for aggressively.
One more thing I want to be direct about: these 10 stocks are highly correlated. If you buy all 10, you’re not as diversified as you think. When AI sentiment cools — and it will at some point — CRWV, NBIS, IREN, and ZETA will all drop together. That’s one bet wearing ten different jerseys.
Investment Portfolio Scenarios
Best Case (20-50% of portfolio to high-risk, high-reward):
AI adoption accelerates faster than expected. Hyperscalers double their 2026 data center capex plans. Neutron launches successfully in Q4 and wins major commercial contracts. All ten companies beat and raise guidance through 2026. Return potential: 300-1000% over 2-3 years.
Base Case (5-10% of portfolio to thematic exposure):
AI growth continues at current rates. Most companies hit their guidance. A few disappoint — likely ASTS (due to SpaceX competition) and AMBA (due to semiconductor cyclicality). Returns are lumpy but the basket outperforms the S&P 500 by 2-3x. Return potential: 50-150% over 2-3 years.
Worst Case (No more than 2-5% in any single name):
AI funding bubble bursts. Hyperscalers cut capex. Neutron fails or delays beyond 2027. Lemonade and Oscar fail to reach profitability. Space stocks correct 60-80% across the board. Return potential: -50% to -80% on individual names.
Who Should Consider This?
- Long-term investors willing to hold through 50% drawdowns for the chance at 5-10X returns
- Growth investors who understand that high growth means high volatility and can stomach it.
- Not For Dividend investors — none of these stocks pay dividends, and they won’t for years.
- High-risk investors comfortable with binary outcomes and the possibility of total loss on individual positions.
Sources
- Oscar Health Q1 2026 Earnings (SEC 8-K, May 2026)
- Nasdaq Quarterly Rebalance June 2026 — TipRanks, Nasdaq.com
- Bank of America Research: CoreWeave and Nebius (March 2026) — TheStreet
- AST SpaceMobile Q1 2026 SEC 10-Q; Trefis Market Analysis
- Barchart: IREN, NBIS, CRWV Momentum Analysis (January 2026)
- WallStreetBets 2026 Index — Finviz.com
- StockTwits / Yahoo Finance: CRWV, NBIS Sentiment (June 2026)
- Simply Wall St: OSCR, ASTS Reports (June 2026)
- AInvest: Nasdaq-100 Rebalance Coverage (June 2026)
- TheStreet: BofA CoreWeave/Nebius Price Target Update
Conclusion
This watchlist represents the best public market opportunities in AI, cloud, and space infrastructure today. The growth numbers are real — 50% to 500% revenue increases across the board. The tailwinds are powerful — agentic AI, data center expansion, national security space spending, and EV adoption all accelerating simultaneously.
But these are early-stage, volatile, and expensive. Half of these stocks could be 10X winners in five years. The other half could go to zero. If that risk profile fits your portfolio, this is the starting point for your research — not the ending point.
“This article is written by Rishav Rajput for dailyStocks7.com. For educational and informational purposes only — not financial advice. I’m not a SEBI-registered advisor. Do your own due diligence before investing.“
FAQs
Oscar Health and Ciena are turning profitable. Oscar targets $250-450 million in operating earnings for 2026. Ciena reported $1.64 adjusted EPS in Q2 2026 — nearly quadruple the prior year. Lemonade and Zeta Global are still unprofitable on a GAAP basis but guided to positive EBITDA in 2026. CoreWeave and Nebius are pre-profitability due to massive capital expenditure needs.
Rocket Lab likely has the most asymmetric upside. If Neutron succeeds, the addressable market expands dramatically. Lemonade and Oscar Health also have strong business models with clear paths to profitability.
No more than 5-10% total across these names unless you have an exceptionally high risk tolerance. Individual positions should rarely exceed 2-3% of total portfolio value. These are speculative growth stocks, not core holdings.
Leave a Reply